CAR-T(CAR-T)细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:CAR-T cell therapy: Advancements in clinical applications and laboratory testing.
CAR-T cell therapy: Advancements in clinical applications and laboratory testing.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
CAR-T 细胞疗法是过继性癌症免疫治疗的代表形式。本综述总结CAR-T 细胞疗法及其临床实践相关实验室检测的最新进展。CAR-T 细胞疗法旨在增强T细胞免疫,与手术、化疗或放疗等传统癌症治疗有所不同。该疗法在血液系统恶性肿瘤中疗效显著,但在许多实体瘤中效果仍有限。目前研究正致力于开发效力更强的CAR-T 细胞,并揭示耐药机制。为拓展临床应用,开发可靠的生物标志物和标准化管理指南至关重要。这些内容包括白细胞单采成功的评估标准、CAR-T 疗效检测、预后或耐药生物标志物,以及用于发现副作用和毒性的实验室检测。临床领域实验室诊断的最新进展,将在CAR-T 细胞疗法时代优化患者管理方面发挥关键作用。
CAR-T cell therapy is a representative form of adoptive cancer immunotherapy. This review summarizes recent advances in CAR-T cell therapy and associated laboratory tests for clinical practice. CAR-T cell therapy is designed to enhance T cell immunity, distinguishing it from conventional cancer treatments such as surgery, chemotherapy, or radiotherapy. It has shown significant efficacy in hematologic malignancies but continues to yield limited results in many solid tumors.
Intensive research efforts are underway to develop more potent CAR-T cells and to uncover mechanisms of resistance. For broader clinical application, the development of reliable biomarkers and standardized management guidelines is essential.
These include criteria for evaluating leukapheresis success, tests for CAR-T efficacy, biomarkers for prognosis or resistance, and laboratory assays for detecting side effects and toxicity. Recent progress in laboratory diagnostics in the clinical field will play a pivotal role in optimizing patient management in the era of CAR-T cell therapy.
MEMBER ACCOUNT
登录成功会直接打开下一页。